According to Coherent Market Insights, the global monoclonal antibodies market is estimated to be valued at US$ 143.5 billion in 2020 and is expected to exhibit a CAGR of 14.4% over the forecast period (2020-2027).
Key Trends and Analysis of the Global Monoclonal antibodies Market:
Key trends in the market include increasing prevalence of cancer, rising regulatory approvals and launch of therapies, increasing research collaborations for the development of robust drugs pipeline, and adoption of collaboration strategies by the companies.
Rising incidence of cancer is expected to increase demand for infusion therapies, thereby contributing to significant growth of the monoclonal antibodies market. For instance, according to the World Cancer Research Fund International’s report, in 2018, breast cancer accounted for the second highest number of cancer cases worldwide, accounting for 2,088,849 new cases worldwide in 2018.
Moreover, increasing research collaborations for the development of robust drugs pipeline is a major factor that is expected to drive the market growth over the forecast period. Success of popular monoclonal antibodies such as Avastin, Herceptin, and Rituxan (revenue as US$ 6.8 Bn, US$ 7.1 Bn, and US$ 5.9 Bn, respectively in 2017 globally) has spurred manufacturers’ interest in these therapies. For instance, in 2018, Novartis AG announced entering into a partnership with MorphoSys and Galapagos for the commercialization and development of human immunoglobulin G1 (IgG1) monoclonal antibody targeting interleukin (IL)-17C.
Rising number of product approvals is expected to drive the market growth. For instance, in March 2019, AbbVie announced receiving approval for SKYRIZI (risankizumab) from Japanese Ministry of Health, Labour and Welfare (MHLW). Also, in March 2019, the U.S. FDA approved Trazimera (trastuzumab-gyyp) for the treatment of metastatic gastric adenocarcinoma and HER2 positive breast cancer.
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2403
Key Market Takeaways:
The global monoclonal antibodies market is expected to exhibit a CAGR of 14.4% over the forecast period, owing to adoption of collaboration strategy by the market players, which is expected to drive the market growth. For instance, in July 2020, UCB announced a license agreement with Roche and Genentech for the development and commercialization of UCB0107, an investigational monoclonal antibody drug, which is a potential treatment for patients with progressive supranuclear palsy (PSP) and Alzheimer’s disease.
An increasing number of government initiatives and funding for clinical trials of drugs, which can be used in the Covid-19 treatment, is projected to favor the market growth. For instance, in March 2020, the World Health Organization launched the ‘Solidarity’ trial, which is a multinational initiative for testing old and new drugs/therapies for treating Covid-19. The trial includes testing four therapies; remdesivir, chloroquine and hydroxychloroquine, lopinavir and ritonavir, lopinavir with ritonavir and interferon-beta.
Key players operating in the global monoclonal antibodies market include Pfizer Inc., Novartis AG, Bayer AG, Sanofi S.A., F. Hoffmann-La Roche AG, Eli Lilly and Co., Merck & Co., Inc., GlaxoSmithKline Plc., AbbVie Inc., Bristol-Myers Squibb, and Regeneron Pharmaceuticals Inc.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2403
Global Monoclonal Antibodies Market, By Source:
Global Monoclonal Antibodies Market, By Application:
- Autoimmune Disease
- Hematological Disease
- Infectious Disease
Global Monoclonal Antibodies Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Monoclonal Antibodies Market, By Region:
- North America
- Rest of Latin America
- Rest of Europe
- South Korea
- Rest of Asia Pacific
- Rest of Middle East
- South Africa
- Central Africa
- North Africa
Related Market Intelligence Report:
Antibodies Market, By Product Type (Monoclonal antibodies, Polyclonal antibodies, Antibody-drug complexes (ADCs)), By Disease Indication (CNS Disorders, Cardiovascular Diseases, Cancer, Autoimmune Disorders), By End User (Hospitals, Long-term Care Facilities, Research institutes), and By Region – Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.